Every night, millions lie awake struggling with insomnia. Rigorous science can change that.
At Avecho, we've designed one of Australia's most advanced sleep studies, a phase III clinical trial investigating our proprietary TPM®-enhanced CBD soft-gel capsule for insomnia.
Our trial has been intentionally designed to meet the standards of key global regulatory agencies including the TGA, FDA, and EMEA, and aided by advice from numerous international sleep experts.
Global pharmaceutical company Sandoz has also placed their trust in Avecho, contributing meaningful upfront investment and securing exclusive Australian commercialisation rights too.
Our trial demonstrates how meticulous study design can advance cannabinoid therapeutics from laboratory promise to bedside reality.
Today we acknowledge the patients who are stepping forward to participate in our trial – and together, hope to restore peaceful sleep for millions who share their struggle.
AVE Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)